2019
The Year We Began Revolutionizing Genomic Medicine with AI
Whitelab Genomics
Passé, présent, futur
Leur histoire
Founded in 2019 by David del Bourgo, Julien Cottineau, and Lucia Cinque, WhiteLab Genomics combines computer science and biology to accelerate the development of genomic medicines. Our AI-powered technology analyzes complex biological data to significantly reduce development timelines and mitigate associated risks. Through in-silico simulations, we design optimized payloads and vectors.
We collaborate with leading pharmaceutical companies like Sanofi, top academic institutions, and innovative biotech firms to accelerate the delivery of life-saving therapies to the market.
Recognized for our contributions to advancing the field of gene and cell therapy, we're part of Y Combinator, the French Tech 2030 Program and have joined Bayer Co.Lab in Cambridge, MA, as well as Ginkgo Bioworks' Technology Network.
15
Awards and Recognitions Celebrating Our Excellence
Valeurs
At WhiteLab Genomics, our 5 Core Values are the foundation of everything we do:
Care: We’re dedicated to making a real difference in the lives of patients and treating every team member with utmost care.
Communication: Open, honest dialogue drives our innovation.
Can-Do Attitude: Obstacles are opportunities in disguise.
Teamwork: We believe that together, we can achieve the extraordinary.
Excellence: We don’t settle for good—we aim for groundbreaking.